Novo Nordisk shares drop sharply in early trading after the company reiterates ambitious growth plans for its obesity drug pipeline. CNBC reports the stock falls by as much as 7%, while Bloomberg similarly describes a steep early selloff.
Novo Nordisk says it aims to launch more than five blockbuster drugs and generate over $23 billion in new sales over the coming years, reflecting its focus on sustaining momentum in obesity treatment. The company’s targets, however, do not fully satisfy investors who are seeking more detailed and “robust” performance guidance and a clearer turnaround plan from CEO Mike Doustdar following changes in the competitive landscape.
Across outlets, the broader context is Novo Nordisk’s loss of market leadership in the obesity category to Eli Lilly. Both reports link the stock decline to investor disappointment about the level of specificity behind the company’s stated sales and launch objectives, despite the scale of the planned growth.
